Ocular Therapeutix, Inc. plans to submit a new drug application for AXPAXLI for wet AMD based on positive data from its SOL-1 Phase 3 clinical trial, expected to report top-line results in Q1 2026. The filing stems from interactions with the FDA regarding their requirements, announced on December 5, 2025.